Veranova Announces $30M Investment in Local Facility

Veranova, a leading developer and manufacturer of specialist and complex APIs for the pharmaceutical and biotech industries, has launched a major expansion at its Devens, MA facility. This $30 million investment aims to enhance the site's capabilities in antibody-drug conjugate (ADC) and highly potent compound development and manufacturing, addressing the increasing demand for robust US-based capacity in these areas.

The expansion project includes the construction of a new high potent process development laboratory and two new cGMP suites. These state-of-the-art facilities are designed to handle compounds with occupational exposure limits (OEL) of less than 0.01 µg/m³. They will be equipped with advanced air handling systems, airlocks for clean-in-place operations, isolator technology, and a comprehensive suite of processing capabilities such as synthesis reactors, chromatography, thin film evaporators, and lyophilization.

Mike Riley, CEO of Veranova, said, “At Veranova, we recognize the growing demand for development and manufacturing of ADCs and other highly potent compounds. This investment signals our commitment to providing state of the art capacity and capabilities to enable these next generation therapies to reach patients, and is a key milestone as we advance our broader growth strategy for Veranova.”

Located strategically near Boston's pharmaceutical and biotech hub, Veranova’s FDA-approved Devens site offers over a decade of expertise in developing, scaling up, and producing ADC linker-payloads and other highly potent APIs for both clinical and commercial use. The Devens facility uniquely integrates development, clinical manufacturing, and commercial manufacturing under one roof, eliminating the need for tech transfers. Additionally, it capitalizes on Veranova’s advanced capabilities in crystallization development and chromatography.